<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03840512</url>
  </required_header>
  <id_info>
    <org_study_id>KAL05</org_study_id>
    <nct_id>NCT03840512</nct_id>
  </id_info>
  <brief_title>An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)</brief_title>
  <official_title>A Phase 2a, Open-label, Multicenter, Study to Evaluate the Pharmacokinetic (PK), Safety and Efficacy of Multiple Doses of Cannabidiol for the Prevention of aGVHD After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kalytera Therapeutics Israel, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kalytera Therapeutics Israel, Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile,
      safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host
      Disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study contains 3 cohorts of 12 participants each: All participants will be orally
      administered for 105 days with CBD at doses of 75, 150 or 300 mg (PO) BID for the prevention
      of acute GVHD (aGVHD) following allogeneic HSCT.

      In addition to the study drug, all participants will receive standard aGVHD prophylaxis
      consisting of a calcineurin inhibitor (cyclosporine or tacrolimus) and a short course of
      methotrexate (MTX). After completion of 105 treatment days, the participant will be
      followed-up until day 180.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Anticipated">November 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) and serious adverse events (SAEs) Reporting</measure>
    <time_frame>Up to day 180</time_frame>
    <description>All AEs will be recorded, whether considered minor or serious, drug-related or not</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of aGVHD at day 100 post-transplant</measure>
    <time_frame>First 100 days after transplant</time_frame>
    <description>Cumulative Incidence of Grade B-D aGvHD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - Cmax</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile - Cmax - Maximum Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - Tmax</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile - Tmax - time to reach maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - Tlag</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile - Tlag - Absorption lag-time defined as the time of the first concentration ≥ Limit of Quantitation (LOQ)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - AUC0-t</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile - AUC0-t - area under the plasma concentration-time curve (AUC0-t) up to the last quantifiable concentration (LOQ) from time of administration (t=0) up to the selected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - λz</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile: λz - Elimination rate constant determined by linear regression of the terminal points of the ln-linear plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - T1/2</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile: T1/2 - Terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of Cannabidiol (CBD) - AUC0-∞</measure>
    <time_frame>Blood samples will be obtained on Day 7 before HSCT and Day 7 post HSCT. Sampling times: immediately after CBD dosing and at 15, 30, 45, 60, 120, 180, and 240 minutes, and 8, 12 and 24 hours after dosing of CBD</time_frame>
    <description>Pharmacokinetic (PK) profile: AUC0-∞ - area under the plasma concentration-time curve extrapolated to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of aGVHD at day 180 post-transplant</measure>
    <time_frame>Day 180 post-transplant</time_frame>
    <description>Cumulative Incidence of Grade 2-4 aGvHD</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Prevention aGVHD</condition>
  <arm_group>
    <arm_group_label>Oral CBD 75 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral CBD 150 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral CBD 300 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBD</intervention_name>
    <description>CBD + Standard aGVHD prophylaxis calcineurin inhibitor (cyclosporine or tacrolimus) + methotrexate (MTX).
Subjects transplanted from unrelated donors or from mismatched siblings will also receive anti-T cell globulin.</description>
    <arm_group_label>Oral CBD 150 BID</arm_group_label>
    <arm_group_label>Oral CBD 300 BID</arm_group_label>
    <arm_group_label>Oral CBD 75 BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any malignant hematological disease in CR or Myelodysplastic Syndrome (MDS)

          2. Age ≥ 18 years

          3. Karnofsky Score (KS) ≥ 60%

          4. HSCT-Comorbidity Index (HSCT-CI) score ≤ 3

          5. No major organ dysfunction

          6. Myeloablative or reduced intensity conditioning regimen

          7. Matched (7/8 or 8/8) unrelated donor

          8. Peripheral blood stem cell graft

          9. Female subjects of childbearing potential must use a medically accepted method of
             contraception and must agree to continue use of this method for the duration of the
             study and for the follow-up time period. Acceptable methods of contraception include
             abstinence, barrier method with spermicide, intrauterine device (IUD), or steroidal
             contraceptive (oral, transdermal, implanted, and injected) in conjunction with a
             barrier method.

         10. Male subjects with partners of childbearing potential must agree to use adequate
             contraception (barrier method or abstinence) during the study.

         11. Subject's written informed consent

        Exclusion Criteria:

          1. Malignant hematological disease other than MDS, not in CR

          2. Myelofibrosis

          3. Allogeneic transplantation from a matched or mismatched sibling donor

          4. Cord blood transplantation

          5. Positive serology for HIV

          6. Serious psychiatric or psychological disorders

          7. Any uncontrolled infection at time of registration

          8. Active consumption of illicit drugs (such as: Crack cocaine, Heroin, Methamphetamines,
             Cocaine, Bath Salts, Amphetamines, Methadone, Benzodiazepine, Ecstasy)

          9. Use of Cannabis and/or its derivatives fourteen days prior to HSCT and for the
             duration of study participation

         10. Uncontrolled hepatitis B or active hepatitis C infection.

         11. QTc&gt;450ms per Fridericia's correction and Impaired cardiac function or clinically
             significant cardiac diseases

         12. Inadequate renal function defined as measured creatinine clearance &gt; 2.0 mg/dl

         13. Liver enzymes: ALT and AST &gt; 3x upper limit of normal

         14. Pregnancy or breastfeeding ((positive serum β-HCG 7 days before first dose)

         15. Treatment with another investigational drug, biological agent, or device within 30
             days of first dose, or investigational cell therapy within 6 months of first dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sari Sagiv, Ph.D.</last_name>
    <phone>+97252854444</phone>
    <email>sari.sagiv@kalytera.co</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney - The Kinghorn Cancer Centre</name>
      <address>
        <city>Sydney</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nada Hamad, M.D.</last_name>
      <phone>+61293555656</phone>
      <email>Nada.Hamad@svha.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care - Bone Marrow Transplantation Unit</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hila Wildbaum</last_name>
      <phone>+972-4-7773248</phone>
      <email>H_WILDBAUM@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Tsila Zuckerman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center - Bone Marrow Transplantation Department, Cancer Immunotherapy and Immunobiology Research Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliane Dray</last_name>
      <phone>+972-2-677-7803</phone>
      <email>LILANE@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Polina Stepensky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Davidof Cancer Center, Beilinson hospital, Rabin medical center</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zvi Shivek Shivek</last_name>
      <phone>+972-3-9377909</phone>
      <email>zvish_@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Liat Shargian, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center - Bone Marrow Transplantation Unit</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sivan Levy</last_name>
      <phone>+972-3-6947249</phone>
      <email>sivanle@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ram Ron, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 10, 2019</study_first_submitted>
  <study_first_submitted_qc>February 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>March 17, 2019</last_update_submitted>
  <last_update_submitted_qc>March 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

